-
公开(公告)号：US20230235060A1
公开(公告)日：2023-07-27
申请号：US18164649
申请日：2023-02-06
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CARINE PATUREL , NICOLAI WAGTMANN
IPC: C07K16/28 , A61K39/395 , C07K16/30
CPC classification number: C07K16/2818 , C07K16/2803 , C07K16/2827 , A61K39/39558 , C07K16/30 , A61K2039/507
Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
-
公开(公告)号：US20190322744A1
公开(公告)日：2019-10-24
申请号：US16448016
申请日：2019-06-21
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CAROLINE SOULAS , NICOLAI WAGTMANN
IPC: C07K16/28
Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
-
公开(公告)号：US20170291947A1
公开(公告)日：2017-10-12
申请号：US15511778
申请日：2015-09-15
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CARINE PATUREL , NICOLAI WAGTMANN
Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
-
公开(公告)号：US20240368281A1
公开(公告)日：2024-11-07
申请号：US18772517
申请日：2024-07-15
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CARINE PATUREL , CAROLINE SOULAS , NICOLAÏ WAGTMANN
IPC: C07K16/28 , A61K39/00 , A61K39/395 , C07K16/30
Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
-
公开(公告)号：US20230303691A1
公开(公告)日：2023-09-28
申请号：US18331966
申请日：2023-06-09
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CAROLINE DENIS , CARINE PATUREL , NICOLAI WAGTMANN
CPC classification number: C07K16/2803 , C07K16/2818 , A61P35/00 , A61K2039/507
Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
-
Patent Agency Ranking
公开(公告)号：US20170313773A1
公开(公告)日：2017-11-02
申请号：US15521401
申请日：2015-10-23
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CAROLINE SOULAS , NICOLAI WAGTMANN
CPC classification number: C07K16/2803 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2863 , C07K2317/24 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: The present disclosure relates to HLA-E as a tumor escape mechanism in head and neck cancer. The disclosure relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
-
公开(公告)号：US20190031755A1
公开(公告)日：2019-01-31
申请号：US16071499
申请日：2017-01-20
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CAROLINE DENIS , CARINE PATUREL , NICOLAI WAGTMANN
Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
-
公开(公告)号：US20170298131A1
公开(公告)日：2017-10-19
申请号：US15511792
申请日：2015-09-15
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CARINE PATUREL , CAROLINE SOULAS , NICOLAÏ WAGTMANN
Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
-
公开(公告)号：US20150125464A1
公开(公告)日：2015-05-07
申请号：US14594353
申请日：2015-01-12
Applicant: Innate Pharma, S.A. , University of Genova
Inventor： ALESSANDRO MORETTA , EMANUELA MARCENARO , FRANCOIS ROMAGNE , PASCALE ANDRE
IPC: C07K16/28 , A61K45/06 , A61K39/395
CPC classification number: C07K16/2896 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/572 , C07K16/2851 , C07K2317/21 , C07K2317/76 , G01N33/56966 , G01N2333/70596 , G01N2500/04
Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.
-
公开(公告)号：US20210238285A1
公开(公告)日：2021-08-05
申请号：US17225160
申请日：2021-04-08
Applicant: INNATE PHARMA
Inventor： PASCALE ANDRE , MATHIEU BLERY , CARINE PATUREL , CAROLINE SOULAS , NICOLAÏ WAGTMANN
IPC: C07K16/28 , A61K39/395 , C07K16/30
Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.017 seconds)
